The acquisition marks a strategic expansion of Warburg’s healthcare holdings, supported by the Abu Dhabi Investment Authority. Pantherx Rare is currently backed by General Atlantic, Nautic Partners, and the Vistria Group. Following the transition, Nautic Partners and the existing management team are set to retain significant ownership stakes in the business.
In section Market Quotes
Warburg Pincus Secures Controlling Stake in Pharmacy Firm Pantherx Rare
A consortium led by private-equity giant Warburg Pincus has finalized an agreement to acquire a controlling interest in Pantherx Rare, a specialty pharmacy dedicated to orphan diseases. While the financial specifics remain undisclosed, reports suggest the transaction values the company at more than $7 billion including debt.
Warburg’s healthcare division head, T.J. Carella, praised the firm for its specialized focus and execution within the rare disease market. The deal, which remains subject to customary closing conditions, is expected to finalize in the coming months.
Comments (0)
No comments yet. Be the first!